Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction<subtitle>The MULTISTRATEGY Randomized Trial</subtitle>

Abstract

HE USE OF ABCIXIMAB, A POtent intravenous antiplatelet agent, and uncoated-stent implantation in the infarctrelated lesion is a complementary treatment strategy that reduces major adverse cardiac events (MACE) in patients undergoing angioplasty (percutaneous coronary intervention [PCI]) for ST-segment elevation myocardial in-Author Affiliations and the MULTISTRATEGY Investigators are listed at the end of this article.

Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST‐segment elevation myocardial infarction: incidence, predictors and clinical outcome

“…The reported incidence of early stent thrombosis in this real‐world STEMI population is relatively high. Nonetheless, the incidence seen in the present study is similar to that reported by the recently published MULTISTRATEGY and subanalysis of the Ongoing Tirofiban In Myocardial infarction Evaluation (On‐TIME) 2 study [4,10]. In another real‐world STEMI population, the reported incidence of early stent thrombosis was as high as 4% [3].…”

Marked reduction of early stent thrombosis with pre‐hospital initiation of high‐dose Tirofiban in ST‐segment elevation myocardial infarction

“…The reported incidence of early ST is relatively high in the On‐TIME 2 trial. Nonetheless, the incidence seen in the present study is similar to the incidence of ST reported by the recently published MULTISTRATEGY study [5]. In a real‐world STEMI population, the reported incidence of early ST was as high as 4% [4,6].…”

Four-Year Follow-Up of TYPHOON (Trial to Assess the Use of the CYPHer Sirolimus-Eluting Coronary Stent in Acute Myocardial Infarction Treated With BallOON Angioplasty)

“…Similar rates were noted in previous studies comparing DES with BMS in STEMI patients (5)(6)(7)(8)(9)(10)(11)(12)(13)(14). Acute coronary syndrome has been described as a predictor of stent thrombosis (34).…”